About this trial
The goal of this clinical trial is to perform a detailed description of the feno- and genotype of people living with type 2 diabetes and severe obesity who are linked to care at Steno Diabetes Center Greenland.
The main questions it aims to answer are:
* Are monogenetic diabetes variants associated with the same risk of developing late diabetic complications as other types of diabetes? * Can genotyping and thereby personalized medicine be implemented in Greenland, and can personalized medicine lead to improved treatment? * What is the prevalence of sleep apnea among high-risk individuals in Greenland? * Is it possible to develop and implement a simple algorithm for the identification of sleep apnea in Greenland that can ensure treatment of severe sleep apnea?
Participants will:
* Answer WHO-5 and FOSQ-10 questionnaires regarding quality of life and functional outcomes of sleepiness * Perform VAGUS examinations for Cardiovasculare Autonomic Neuropathy * Clinical examination of height, weight, circumference of hip, waist and neck, Friedman tonsil and tongue score, nasal air flow, nasal septal deviation * Blood samples for full genome sequencing
Eligibility criteria
Qualifiers
Type 2 diabetes and/or morbid obesity (BMI >40)
Over 18 years old
Disqualifiers
Does not speak either English, Danish or Greenlandic
Trial design
Treatments tested in this trial
- Whole genome sequencing
- VAGUS
- NightOwl
- CPAP
Treatment groups
Sponsors and collaborators
Steno Diabetes Center Greenland
Lead sponsor
Zealand University Hospital
Collaborator
University of Copenhagen
Collaborator